101.5
[1]. Ferraris O, et al. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 2005 Oct;8(1):-8.
[2]. Ghosh GC, et al. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect. 2010 Jan;118(1):10-7.
[]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Antimicrob Agents Chemother. 2001 Dec;5(12):0-8.
[]. Hoffmann G, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;5(11):75-1.
[5]. Li W, et al. Identification of GS 10 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 071. Antimicrob Agents Chemother. 1998 Mar;2():7-5.
H02-H15-H19-H5
P21-P2-P270-P271-P280-P02+P52-P0+P0-P05+P51+P8-P0-P2+P-P0+P2-P05-P501